Eli Lilly Shares Drop 10.5% Amid Rising Competition

Eli Lilly and Company shares fell approximately 10.5% from a 52-week high of $1,292.65, trading at $1,157.27 as of August 31, 2026. The pullback occurs despite significant financial growth, with revenue increasing from $28.3 billion in fiscal year 2021 to $65.2 billion in fiscal year 2025 and a return on equity of 102.4% as of June 30, 2026.

The company recently expanded its portfolio through the $2.875 billion acquisition of Merida Biosciences to integrate an autoantibody degradation platform. Additionally, the Food and Drug Administration approved Mounjaro on August 27 for cardiovascular risk reduction in patients with Type 2 diabetes.

Market pressures include a high debt-to-equity ratio of 162.1% and a price-to-earnings ratio of 39.2x. The company also faces intensifying competition from Novo Nordisk, specifically regarding the rapid global approval and rollout of oral Wegovy in markets such as China.